Adewole L F, Rustin G J, Newlands E S, Dent J, Bagshawe K D
Eur J Cancer Clin Oncol. 1986 Dec;22(12):1479-82. doi: 10.1016/0277-5379(86)90083-0.
The effect of etoposide containing drug combinations on reproductive performance was studied in women successfully treated for gestational trophoblastic disease between 1977 and 1984. Of the 74 women who wished to get pregnant 57 (77.0%) succeeded in having at least one live birth while five (6.8%) have ongoing pregnancies. Of eight (19.8%) women who have not become pregnant two (2.7%) had previous infertility problems antedating the development of gestational trophoblastic disease. The miscarriage rate was 124/1000. There was only one case of foetal death and one congenital abnormality (microcephaly possibly associated with cytomegalovirus infection) among 79 live births and stillbirths. This study indicates that etoposide (VP16-213) as is currently used in this unit for the treatment of gestational trophoblastic tumour is unlikely to have any long-term effect on fertility in most women.
1977年至1984年间,对成功接受治疗的妊娠滋养细胞疾病女性患者,研究了含依托泊苷的联合用药对生殖性能的影响。在74名希望怀孕的女性中,57名(77.0%)成功至少生育了一个活产婴儿,5名(6.8%)仍在妊娠中。在8名(19.8%)未怀孕的女性中,2名(2.7%)在妊娠滋养细胞疾病发生之前就存在既往不孕问题。流产率为124/1000。在79例活产和死产中,仅有1例胎儿死亡和1例先天性异常(小头畸形,可能与巨细胞病毒感染有关)。本研究表明,本单位目前用于治疗妊娠滋养细胞肿瘤的依托泊苷(VP16 - 213)在大多数女性中不太可能对生育能力产生任何长期影响。